VERTEX PHARMACEUTICALS INC / MA

Key metrics

Financial performance

Over the last 9 fiscal years VERTEX PHARMACEUTICALS INC / MA's revenue grew from $1.70B to $12.00B, a compound annual growth rate of 24.2%. Net profit margin expanded from -6.6% to 32.9% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,000 filings)

Recent press releases

• Vertex Reports Second Quarter 2025 Financial Results

  Total revenue increased 12% to $2.96 billion compared to the second quarter of 2024, primarily driven by the continued performance of cystic ...

• Vertex Provides Pipeline and Business Updates in Advance of ...

  Vertex realized its goal for greater than $100 million of CASGEVY revenue in 2025, reflecting more than 60 patients receiving infusions of CASGEVY. At the ...

• Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

  Vertex Reports Fourth Quarter and Full Year 2025 Financial Results ; FY 2026 ; Total revenue. $12.95 to $13.1 billion ; Non-CF product revenue.

• Vertex Reports First Quarter 2025 Financial Results

  Total revenue of $2.77 billion , a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new ...

• Vertex Reports Third Quarter 2025 Financial Results

  Total revenue increased 11% to $3.08 billion compared to the third quarter of 2024, primarily driven by the continued performance of cystic ...

Similar companies

The largest companies sharing VERTEX PHARMACEUTICALS INC / MA's SEC industry classification (pharmaceutical preparations).